US EditionPublished • loading... • Updated
FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event
- The FDA has approved Novo Nordisk's oral semaglutide for reducing cardiovascular risk in adults with type 2 diabetes who are at high risk, including those without a prior cardiovascular event.
- The SOUL trial results support the clinical profile of semaglutide, which has been studied in various therapeutic areas.
- Adults with type 2 diabetes face a higher risk of cardiovascular events, highlighting the need for therapies that address more than just blood sugar levels.
- Oral semaglutide demonstrated a 14% relative reduction in risk of major adverse cardiovascular events over four years compared to placebo.
Insights by Ground AI
48 Articles
48 Articles
The Berkshire Eagle+47 Reposted by 47 other sources
FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event
Rybelsus® (semaglutide) tablets 7 mg or 14 mg, the only FDA-approved oral GLP-1 medicine available, now indicated to reduce the risk of major adverse cardiovascular events (MACE) such as CV death, heart attack, or stroke in adults with type 2…
Coverage Details
Total News Sources48
Leaning Left5Leaning Right5Center14Last UpdatedBias Distribution58% Center
Bias Distribution
- 58% of the sources are Center
58% Center
L 21%
C 58%
R 21%
Factuality
To view factuality data please Upgrade to Premium
